John Connolly, Ph.D., interim CEO, and Hanspeter Gerber, Ph.D., Chief Scientific Officer, will participate in the BIO CEO & Investor Digital Conference, February 16-18, 2021. Dr. Connolly, will present an overview of the company and 3T-TRACE, a technology that applies a yeast display platform and…
John Connolly, Ph.D., interim CEO of 3T Biosciences, will present an overview of the company and 3T-TRACE, a technology that applies a yeast display platform and active machine learning to identify novel targets and T-cell receptors (TCRs), at the Biotech Showcase Digital conference. Hanspeter Gerber,…
Media contact: Lissa Quirino, pr@3tbiosciences.com SOUTH SAN FRANCISCO, Calif., - December 16, 2020 -- 3T Biosciences, an immunotherapy company, today announced that John Connolly, Ph.D. has been appointed as interim CEO. Together with the current leadership team, Dr. Connolly will lead the next round of…